Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v9-FR Version v4-EN
Language French English
Date Updated 2017-11-15 2017-09-29
Drug Identification Number 02266342 02266342
Brand name FLUMAZENIL INJECTION FLUMAZENIL INJECTION
Common or Proper name Flumazenil Injection, USP 0.1mg/mL MD Vial Flumazenil Injection, USP 0.1mg/mL MD Vial
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients FLUMAZENIL FLUMAZENIL
Strength(s) 0.1MG 0.1MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 5mL 5mL
ATC code V03AB V03AB
ATC description ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2017-10-10 2017-10-10
Actual start date 2017-10-10
Estimated end date 2017-11-15 2017-11-15
Actual end date 2017-11-17
Shortage status Actual shortage Anticipated shortage
Tier 3 Status No No
Company comments Stock available for direct orders on Friday November 17, 2017 and in all distribution centers on Tuesday November 21, 2017. Product on reduced allocation. Sandoz Canada Inc. is the alternate supplier of Flumazenil Injection, USP 0.1mg/mL and has been notified of our shortage. Sandoz will be limiting order quantities to help ensure consistent supply to the market until our return.
Health Canada comments